{"name":"Illumina, Inc.","slug":"illumina","ticker":"ILMN","exchange":"NASDAQ","domain":"illumina.com","description":"Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.","hq":"San Diego, CA","founded":0,"employees":"8600","ceo":"Jacob Thaysen","sector":"Life Sciences Tools & Diagnostics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":145.3,"stockChange":0.3,"stockChangePercent":0.21,"marketCap":"$22.0B","metrics":{"revenue":4392999936,"revenueGrowth":4.8,"grossMargin":68.3,"rdSpend":967000000,"netIncome":850000000,"cash":1155000064,"dividendYield":0,"peRatio":26.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Illumina Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Illumina reported fourth quarter and full year 2023 financial results, with revenue of $1.4 billion and net income of $243 million.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Illumina to Acquire GRAIL, Inc.","summary":"Illumina announced that it has entered into a definitive agreement to acquire GRAIL, Inc., a healthcare technology company focused on cancer detection.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves Illumina's TruSight Oncology 500","summary":"The FDA has approved Illumina's TruSight Oncology 500, a next-generation sequencing (NGS) test for the detection of genetic variants associated with cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1SZTJmRE91dTNvTmY0QURsZWZJbXBiUWxqUGYzRi1lOFFvTmF3U0Y1eHZUV2hocXFOVjlVX1BqNlBzamU1VnljZFlydXhfRUNlTTlrcW1FOElTNy13ZnJFYjljUm9PN2czZm44WTF6RURhUE9ueWlCV2xJQmh1RHc?oc=5","date":"2026-01-20","type":"pipeline","source":"Yahoo Finance","summary":"Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Yahoo Finance","headline":"Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPX0JtOEZxZGR6eXdOQ0NneW5jUWN4XzN2MGJDUXgxQUFqNWREX2ZKVVFDcDZXZVRCa2pVNnZNcjhyQmVEbU9JMGxzbldNMDJxbXFsczRBQjBCX3VkRVJUeGdLbG1BdVFnWEpJQXNrM0lUb1hveDZETkFoT3VfRzZGXw?oc=5","date":"2026-01-19","type":"pipeline","source":"Yahoo Finance","summary":"The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance","headline":"The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPSG1PbGxRSV9hWmdQTGZlNmRGMWM4MzJ3LTc4UXBJbjVLRi1RcFB2ODZKZUF5ODlxak40TzVCQ0wyT0xHRlVLcFR1Sk1TaU82MGh2bUpvODAwZlNtT2R1cEdYOW1MZklYR2xBYzlHbkVRUVVMNk5kc1Bwbjl2Rkw2ZXlFOVpBM0RoQzBQWDhtMWJ2S0VqSzAxWGpaTjZsYTgxQkpQdTUxY3haZw?oc=5","date":"2026-01-15","type":"deal","source":"Mugglehead Magazine","summary":"Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine","headline":"Illumina partners with pharma giants to map disease biology at unprecedented scale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPVFBXa1Q0a3QtalU3ZnFGYUJucXlEOEdxQl9Lb2p2dXlEbDkwalBwZEw3b1hNUVN6MG9rZzh0bU1iSDN3ZHlLOU1INnRJSU9DVGRUMjB5Z0NSd0NLeGs1S0g5RTNnQm0tY1FpZFIxRWpEMGYzV3d2c1dMeFJZU2hBYVdnVnAydmlKVl9JWjFJWXMwcWVzOV9fX3pyaUJhNU4zaXRsbEFrMnZLVVFLXzNIallyNUt2UkFIQ1BJZldhcUdpLWl4TU4zYTdHWQ?oc=5","date":"2026-01-13","type":"trial","source":"Reuters","summary":"Illumina unveils dataset to speed up AI-powered drug discovery - Reuters","headline":"Illumina unveils dataset to speed up AI-powered drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOeU5SZENMc0pidXVObWZnRkJPVVZ4N2RLYnJwcnZLTGNpcERaYUFLaS1aRlRaX24wVVMtdm81ZkZmTmFiSnZKUTlhb1V1Q1U5dXNmMUpXSUJodUFwQWdXbEltYThGOFctazB2bWNFVTZGcGVUb2ROZ0NzbnViUjBybV9CaGNLM0tpRXhIYjU4alRWclZCbHYwUktMN3lFUkFVa3FuUUY3TWwtXzNaaTdXdW1yeExUOWY3WkxueFZGUGVNYldmZGdDZFlB?oc=5","date":"2026-01-13","type":"pipeline","source":"PR Newswire","summary":"Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - PR Newswire","headline":"Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTUhtNXI0Y3RxYUdQTkNGaFI2eWJDel9mSnB3LUg3TTBhdWhPRU8xUGRNbU5qc3hGMXlIZmg2RWRGdTI5VlBhVlVoSnp5eWxyZDhDakZub0pPeElDeGktOXVETFdxcktCNUR1bndfcHZwaWR1NTNpdi1xazVuWEZnc1RfV21XT2l2NS1UZG03YlhidENXS2ktaGxLR0dkTDdFMzVaZmpkR2JRUG44R2p5ZVF0cVVRSmNfMnBFUE5tWkw?oc=5","date":"2026-01-12","type":"pipeline","source":"TradingView","summary":"Illumina's New Connected Multiomics Platform Set to Boost Its Stock - TradingView","headline":"Illumina's New Connected Multiomics Platform Set to Boost Its Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GV2tSdkx6b2hma1FNalhjNC1CZ2c3SzhjLVV6VkhIRjRNS2RKTFFQamFhOXdJTmtVQnlCY0F1clVuQmoxV055Y01XWDNSREJqUExYVUlCWkhrcjZZdDRJ?oc=5","date":"2025-11-27","type":"pipeline","source":"Intellectia AI","summary":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine - Intellectia AI","headline":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNdndRQ2lSLU92cGF0V1ZIM2NERjVENnlMclJDcWk4aEtUd2ltMVMwcVhxeUZxVG1QXy1jWWZzdnFWRWhUejRBZXRFQ0VudU9FcUVDYk95bUJTZ1Q4MzBCSjJWdl9pY2ZIc3U0RVZoeC1hRVRNRGZlLVpUZHNJLUFCdUNHNlpvTU1rVFBQdnNsb3BqOEdQQ000akZCclhWX1I4RFM2Zkc4YkY3ajBkNm8yOU53NF9NRDFFZkJTeERlS25jR2JsaVpPbFBRU1pna3EtYUFMOXIyQllJb3JVUUZMaFA4eVI3OWNVQ2FfWUYwU1dseEI1WlZYVGxXMWhZTWF1bEhQNExYSlU4UEl3aG1n?oc=5","date":"2025-10-10","type":"pipeline","source":"TradingView","summary":"10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView","headline":"10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNY3NobmItR3JGRXFaTE42V3Y3WTBNU1Zkano4ZmtYZ21kUnBKVENsZjRKYTJ4VTVwaDB2MHBpWHdseWFyVXFNOVhVTlBrQVh5Nm9OR3VaOWZ0UnkyMjl5NHFSb29IZk90UXcwQWVQelIzOXp6bkRwTzFMQ3hmNk9TZTlhRjNyeUZDdlUtSzlfel9WQnM2QkhpNDZRV3A2aDlPdkk5Zy1scXJ2NWZfeVFnWHhBTXhHSDVFcUNyWFZpUXEyRm84Z0Y3bnpMMFVGNFpWS1N3?oc=5","date":"2025-10-01","type":"trial","source":"PR Newswire","summary":"Illumina launches new business to accelerate technology and data-driven discovery - PR Newswire","headline":"Illumina launches new business to accelerate technology and data-driven discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQbUVaUjJGektwa1dMY0Z2emprV2NabzNTTVBmNk5VUkZUS2tzMTF1bmllbVktYy1VdkdDZG12cVB0dm1SMV9xWEJpaWpHSGY3eHhPdURzVXBQa2lMbzNCb0ZQQ1J6ckpwOGd6Y0ZOWm91enpGVHhSRUxVS041dnozc1ZITTNiSzg1cHZjQWlrQzg3LWpIQkRad3JqNmhRd25oLU91bGtTWkZocE9kYXMwSVdBeUZwd1hNSGxxaU9oZHlOdTllakpXaWlWUkZqVkd5WmlCbGtn?oc=5","date":"2025-09-23","type":"deal","source":"PR Newswire","summary":"Illumina advances personalized cancer care with new pharma development partnerships - PR Newswire","headline":"Illumina advances personalized cancer care with new pharma development partnerships","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZUJVSTRYMHprZEUzN01DUEtfNHRjS0czOU9QYkhrWXJiWXN4eWpUTHFNQWk4NE9jTzJrS2NKNk1IS0FLY0txNzFDMHJHeWJwNGZMVU5GTzlKNVpUTDdlOWMyMnR2djZoVjF4djdPNFh1UGlPU0NmZzM0Nnd5ZVFSM05WdWxoSXMzRmJGOHdMd01NNmtwc0wtc1FFUHlhRjNUS3h2VmRtWEp6UQ?oc=5","date":"2025-09-18","type":"trial","source":"Illumina","summary":"Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - Illumina","headline":"Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZHA0aTM0Z0h1SmJQMDZWZXdBdkZkOE5wYWR0YkVEMFNJZ040UWpxRVR3Wld0Slk4blNEUWNGU2JzVHdnZHU2dzRQaUR3TTdlYWxuQzZsSXFiUXY4ckFvdWFhcVRqNkNxbEc5ZzFfelFkeFRQZjNjUDhQNUVNV05MaG9Lbm9QOTBaaVVpQTdoVHdXOW5YdzhFZWNST1Nmd0FmVjd4NThLcXNiM3c?oc=5","date":"2025-08-02","type":"pipeline","source":"Yahoo Finance","summary":"Pharma interest can plug NIH funding gap: Illumina CEO - Yahoo Finance","headline":"Pharma interest can plug NIH funding gap: Illumina CEO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Thermo Fisher Scientific","Qiagen","Roche Holding"],"therapeuticFocus":["Genetic Testing","Gene Expression Analysis","Epigenetic Analysis"],"financials":{"source":"sec_edgar+yahoo","revenue":4343000000,"revenuePeriod":"2025-12-28","revenueHistory":[{"value":4343000000,"period":"2025-12-28"},{"value":4372000000,"period":"2024-12-29"},{"value":4372000000,"period":"2024-12-29"},{"value":4504000000,"period":"2023-12-31"},{"value":4504000000,"period":"2023-12-31"}],"grossProfit":2870000000,"grossProfitHistory":[{"period":"2025-12-31","value":2870000000},{"period":"2024-12-31","value":2861000000},{"period":"2023-12-31","value":2744000000},{"period":"2022-12-31","value":2972000000}],"rdSpend":967000000,"rdSpendHistory":[{"period":"2025-12-31","value":967000000},{"period":"2024-12-31","value":1169000000},{"period":"2023-12-31","value":1354000000},{"period":"2022-12-31","value":1321000000}],"sgaSpend":1086000000,"operatingIncome":817000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":817000000},{"period":"2024-12-31","value":600000000},{"period":"2023-12-31","value":-222000000},{"period":"2022-12-31","value":354000000}],"netIncome":850000000,"netIncomeHistory":[{"period":"2025-12-31","value":850000000},{"period":"2024-12-31","value":-1223000000},{"period":"2023-12-31","value":-1161000000},{"period":"2022-12-31","value":-4404000000}],"eps":5.45,"epsHistory":[{"period":"2025-12-31","value":5.45},{"period":"2024-12-31","value":-7.69},{"period":"2023-12-31","value":-7.34},{"period":"2022-12-31","value":-28}],"cash":1418000000,"cashHistory":[{"period":"2025-12-31","value":1418000000},{"period":"2024-12-31","value":1127000000},{"period":"2023-12-31","value":1048000000},{"period":"2022-12-31","value":2011000000}],"totalAssets":6644000000,"totalLiabilities":3921000000,"totalDebt":2553000000,"equity":2723000000,"operatingCashflow":1079000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":1079000000},{"period":"2024-12-31","value":837000000},{"period":"2023-12-31","value":478000000},{"period":"2022-12-31","value":392000000}],"capex":-148000000,"capexHistory":[{"period":"2025-12-31","value":-148000000},{"period":"2024-12-31","value":-128000000},{"period":"2023-12-31","value":-195000000},{"period":"2022-12-31","value":-286000000}],"freeCashflow":931000000,"dividendsPaid":null,"buybacks":-742000000,"employees":8600,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":272000000,"ebit":181000000,"ebitda":250000000,"period":"2026-03-31","revenue":1091000000,"epsBasic":0.88,"netIncome":134000000,"rdExpense":240000000,"epsDiluted":0.87,"grossProfit":721000000,"operatingIncome":209000000},{"sga":309000000,"ebit":403000000,"ebitda":469000000,"period":"2025-12-31","revenue":1159000000,"epsBasic":2.18,"netIncome":334000000,"rdExpense":239000000,"epsDiluted":2.16,"grossProfit":759000000,"operatingIncome":211000000},{"sga":277000000,"ebit":245000000,"ebitda":312000000,"period":"2025-09-30","revenue":1084000000,"epsBasic":0.98,"netIncome":150000000,"rdExpense":229000000,"epsDiluted":0.98,"grossProfit":733000000,"operatingIncome":227000000},{"sga":234000000,"ebit":331000000,"ebitda":399000000,"period":"2025-06-30","revenue":1059000000,"epsBasic":1.49,"netIncome":235000000,"rdExpense":247000000,"epsDiluted":1.49,"grossProfit":695000000,"operatingIncome":214000000},{"sga":267000000,"ebit":207000000,"ebitda":276000000,"period":"2025-03-31","revenue":1041000000,"epsBasic":0.83,"netIncome":131000000,"rdExpense":252000000,"epsDiluted":0.82,"grossProfit":683000000,"operatingIncome":164000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":145.3,"previousClose":145,"fiftyTwoWeekHigh":155.53,"fiftyTwoWeekLow":78.55,"fiftyTwoWeekRange":"78.55 - 155.53","fiftyDayAverage":128.4,"twoHundredDayAverage":119.61,"beta":1.42,"enterpriseValue":23327500288,"forwardPE":24.6,"priceToBook":8.31,"priceToSales":5,"enterpriseToRevenue":5.31,"enterpriseToEbitda":20.2,"pegRatio":2.51,"ebitda":1155000064,"ebitdaMargin":26.3,"freeCashflow":845625024,"operatingCashflow":1128000000,"totalDebt":2544000000,"debtToEquity":95.1,"currentRatio":1.75,"returnOnAssets":8.7,"returnOnEquity":33.8,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":18,"targetMeanPrice":140.67,"targetHighPrice":175,"targetLowPrice":95,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.2,"institutionHeldPercent":105.7,"sharesOutstanding":151300000,"floatShares":147053009,"sharesShort":6546522,"shortRatio":4.68,"shortPercentOfFloat":4.3,"epsTrailing":5.5,"epsForward":5.91,"revenuePerShare":28.62,"bookValue":17.49,"officers":[{"age":50,"name":"Mr. Jacob  Thaysen Ph.D.","title":"CEO, Interim Chief Commercial Officer & Director"},{"age":49,"name":"Mr. Ankur  Dhingra CPA","title":"Chief Financial Officer"},{"age":57,"name":"Mr. Kevin Carl Pegels","title":"Chief of Global Operations"},{"age":64,"name":"Dr. Steven  Barnard Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Stephanie  Campos","title":"President"},{"age":52,"name":"Mr. Scott  Ericksen","title":"VP & Chief Accounting Officer"},{"age":54,"name":"Mr. Mark  Field","title":"Chief Information Officer"},{"age":null,"name":"Mr. Conor Noel  McNamara C.F.A.","title":"VP of Investor Relations"}],"industry":"Diagnostics & Research","irWebsite":"http://investor.illumina.com/phoenix.zhtml?c=121127&p=IROL-irhome","website":"https://www.illumina.com","phone":"858 202 4500"}}